Marinus Pharmaceuticals (MRNS) Receiving Somewhat Positive Media Coverage, Report Finds

News stories about Marinus Pharmaceuticals (NASDAQ:MRNS) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Marinus Pharmaceuticals earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.3590761744506 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Marinus Pharmaceuticals (NASDAQ MRNS) traded down $0.19 during mid-day trading on Monday, reaching $6.22. The company’s stock had a trading volume of 613,800 shares, compared to its average volume of 972,667. Marinus Pharmaceuticals has a 52 week low of $1.13 and a 52 week high of $9.87. The company has a market capitalization of $251.48, a P/E ratio of -6.69 and a beta of 2.10.

A number of analysts recently weighed in on the company. HC Wainwright initiated coverage on Marinus Pharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $33.00 target price for the company. BidaskClub cut Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Laidlaw began coverage on Marinus Pharmaceuticals in a research note on Thursday, December 14th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, ValuEngine cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Marinus Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $20.67.

In other Marinus Pharmaceuticals news, CEO Christopher Michael Cashman sold 9,566 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $6.28, for a total transaction of $60,074.48. Following the completion of the transaction, the chief executive officer now owns 247,903 shares in the company, valued at approximately $1,556,830.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bain Capital Life Sciences Inv sold 822,547 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $8.10, for a total value of $6,662,630.70. The disclosure for this sale can be found here. Insiders have sold 2,107,660 shares of company stock valued at $16,774,106 in the last quarter. 6.40% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Insider Buying and Selling by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply